An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Trial Profile

An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs AVB 620 (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Avelas BioSciences
  • Most Recent Events

    • 03 Aug 2017 According to an Avelas Biosciences media release, the first patient has been dosed in this study.
    • 10 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 10 Apr 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top